Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Iressa Postmarketing Trial Modeled On Tarceva Phase III Under Consideration

May 05 2003

• By The Pink Sheet

Related Content

Iressa User Fee Date Pushed To May; Will Advisory Cmte. Take Second Look?

Jan 13 2003

Iressa Cross-Over Study Could Show Clinical Benefit, AZ Says; ODAC Is Wary

Sep 30 2002

AstraZeneca Iressa Focus Is Sequential Therapy After INTACT Studies Fail

Aug 26 2002

Genentech Tarceva Trials “On Track” Despite INTACT: Response To Iressa

Aug 26 2002

AstraZeneca Iressa NDA Filing Complete: Will HIV Model Fly In Oncology?

Aug 12 2002

Iressa NDA Awaits CMC Data; Oncology Response Rates Under Scrutiny At FDA

May 27 2002

AstraZeneca Iressa NDA Review Complicated By Pneumonia Reports

Nov 04 2002

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window